Search research articles
Contact Us
Filters
Showing results (1-10 of 86) with videos related to
Page
of 9
Sort By:
Current Pharmaceutical Design
|
July 17, 2010
News in therapy of cardiomyopathy
Giovanni Fazio
Pharmaceuticals (Basel, Switzerland)
|
October 8, 2016
Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors?
Salvatore Novo, Giovanni Fazio, Elena Raccuglia
Current Pharmaceutical Design
|
July 17, 2010
Neuromuscular disorders in left ventricular hypertrabeculation/noncompaction
Josef Finsterer, Claudia Stöllberger, Giovanni Fazio
Current Pharmaceutical Design
|
September 23, 2010
Antithrombotic therapy in cardiovascular and haematological diseases: new perspectives
Sergio Siragusa, Giovanni Fazio, Giuseppe Barbaro
Recenti Progressi in Medicina
|
November 27, 2014
[Sudden cardiac death in athletes: is it always not preventable?]
Federica Vernuccio, Giuseppe Grutta, Giovanni Fazio
Giornale Italiano Di Cardiologia (2006)
|
November 30, 2006
[Pacemaker implantation in children: is this a therapy or a pathogenetic mechanism for ventricular dysfunction?]
Giovanni Fazio, Massimo Stefano Silvetti, Fabrizio Drago
European Heart Journal
|
May 2, 2007
The chronic heart failure is not so frequent in non-compaction
Giovanni Fazio, Loredana Sutera, Giovanni Corrado, et al.
Current Pharmaceutical Design
|
July 17, 2010
Takotsubo cardiomyopathy
Keisuke Kida, Yoshihiro J Akashi, Giovanni Fazio, et al.
World Journal of Cardiology
|
May 16, 2013
Drugs to be avoided in patients with long QT syndrome: Focus on the anaesthesiological management
Giovanni Fazio, Federica Vernuccio, Giuseppe Grutta, et al.
International Journal of Cardiology
|
March 21, 2007
Symptomatic acute myocardial infarction in a patient bearer of heart transplantation following ischemic heart disease
Giovanni Fazio, Loredana Sutera, Daniela Vernuccio, et al.
Page
of 9
Search research articles
Search
Showing results (1-10 of 86) with videos related to
Sort By:
Page
of 9
Current Pharmaceutical Design
|
July 17, 2010
News in therapy of cardiomyopathy
Giovanni Fazio
Pharmaceuticals (Basel, Switzerland)
|
October 8, 2016
Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors?
Salvatore Novo, Giovanni Fazio, Elena Raccuglia
Current Pharmaceutical Design
|
July 17, 2010
Neuromuscular disorders in left ventricular hypertrabeculation/noncompaction
Josef Finsterer, Claudia Stöllberger, Giovanni Fazio
Current Pharmaceutical Design
|
September 23, 2010
Antithrombotic therapy in cardiovascular and haematological diseases: new perspectives
Sergio Siragusa, Giovanni Fazio, Giuseppe Barbaro
Recenti Progressi in Medicina
|
November 27, 2014
[Sudden cardiac death in athletes: is it always not preventable?]
Federica Vernuccio, Giuseppe Grutta, Giovanni Fazio
Giornale Italiano Di Cardiologia (2006)
|
November 30, 2006
[Pacemaker implantation in children: is this a therapy or a pathogenetic mechanism for ventricular dysfunction?]
Giovanni Fazio, Massimo Stefano Silvetti, Fabrizio Drago
European Heart Journal
|
May 2, 2007
The chronic heart failure is not so frequent in non-compaction
Giovanni Fazio, Loredana Sutera, Giovanni Corrado, et al.
Current Pharmaceutical Design
|
July 17, 2010
Takotsubo cardiomyopathy
Keisuke Kida, Yoshihiro J Akashi, Giovanni Fazio, et al.
World Journal of Cardiology
|
May 16, 2013
Drugs to be avoided in patients with long QT syndrome: Focus on the anaesthesiological management
Giovanni Fazio, Federica Vernuccio, Giuseppe Grutta, et al.
International Journal of Cardiology
|
March 21, 2007
Symptomatic acute myocardial infarction in a patient bearer of heart transplantation following ischemic heart disease
Giovanni Fazio, Loredana Sutera, Daniela Vernuccio, et al.
Page
of 9